# Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

> **NCT03784625** · EARLY_PHASE1 · COMPLETED · sponsor: **Centre Jean Perrin** · enrollment: 10 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** [131I]ICF01012 (therapeutic dose level 1)
- **DRUG:** [131I]ICF01012 (therapeutic dose level 2)
- **DRUG:** [131I]ICF01012 (therapeutic dose level 3)
- **DRUG:** [131I]ICF01012 (therapeutic dose level 4)

## Key facts

- **NCT ID:** NCT03784625
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03784625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03784625, "Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03784625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*